JP2002543118A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002543118A5 JP2002543118A5 JP2000614987A JP2000614987A JP2002543118A5 JP 2002543118 A5 JP2002543118 A5 JP 2002543118A5 JP 2000614987 A JP2000614987 A JP 2000614987A JP 2000614987 A JP2000614987 A JP 2000614987A JP 2002543118 A5 JP2002543118 A5 JP 2002543118A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pioglitazone
- metformin
- pharmaceutically acceptable
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 27
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 18
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 9
- 229960003105 metformin Drugs 0.000 description 9
- 229960005095 pioglitazone Drugs 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 8
- 229960001476 pentoxifylline Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13167599P | 1999-04-29 | 1999-04-29 | |
| US60/131,675 | 1999-04-29 | ||
| PCT/US2000/011355 WO2000066102A2 (en) | 1999-04-29 | 2000-04-28 | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002543118A JP2002543118A (ja) | 2002-12-17 |
| JP2002543118A5 true JP2002543118A5 (enExample) | 2007-06-28 |
Family
ID=22450526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000614987A Pending JP2002543118A (ja) | 1999-04-29 | 2000-04-28 | ペントキシフィリン、ピオグリタゾンおよびメトフォルミンは、後期糖化最終生成物（ａｇｅ）の形成の阻害剤である |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20020123501A1 (enExample) |
| EP (1) | EP1210087A2 (enExample) |
| JP (1) | JP2002543118A (enExample) |
| AU (1) | AU776162B2 (enExample) |
| CA (1) | CA2371391A1 (enExample) |
| WO (1) | WO2000066102A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787566B2 (en) * | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
| US6589944B1 (en) * | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
| US7030133B2 (en) | 1999-04-05 | 2006-04-18 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGEs) |
| DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| GB0312122D0 (en) * | 2003-05-27 | 2003-07-02 | Pharmagene Lab Ltd | Therapeutic method |
| EP1682114A2 (en) | 2003-10-27 | 2006-07-26 | City of Hope | Methods of lowering lipid levels in a mammal |
| US20090088367A1 (en) * | 2004-05-10 | 2009-04-02 | Burnham Institute For Medical Research | Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| JP2009515885A (ja) | 2005-11-11 | 2009-04-16 | オーロゲン インコーポレイテッド | 組織の収縮又は萎縮に関連する成人中枢神経系の疾病又は障害をインスリン投与によって治療する方法 |
| EP2001470A2 (en) * | 2006-03-16 | 2008-12-17 | Metabolic Solutions Development Company | Combination therapies of thiazolidinedione analogues |
| DE102007041232A1 (de) | 2007-08-30 | 2009-03-05 | Henkel Ag & Co. Kgaa | Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs |
| US8563500B2 (en) | 2007-09-05 | 2013-10-22 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Methods and compounds for treating diseases caused by reactive oxygen species |
| EP2203433B1 (en) * | 2007-09-14 | 2012-10-31 | Metabolic Solutions Development Company LLC | 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes |
| US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
| DE102007054653A1 (de) | 2007-11-14 | 2009-05-20 | Henkel Ag & Co. Kgaa | Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| US8815508B2 (en) | 2008-08-12 | 2014-08-26 | Zinfandel Pharmaceuticals, Inc. | Method of identifying disease risk factors |
| GB2465796A (en) * | 2008-12-01 | 2010-06-02 | Bee Kang Tan | Metformin for the therapeutic use of conditions with raised serum amyloid A levels |
| AU2010225923B2 (en) * | 2009-03-16 | 2016-10-27 | Ipintl, Llc | Treating Alzheimer's disease and osteoporosis and reducing aging |
| EP2470510B1 (en) | 2009-09-30 | 2014-05-14 | TransTech Pharma, LLC | Substituted imidazole derivatives for treatment of alzheimers disease. |
| US8912335B2 (en) | 2009-12-15 | 2014-12-16 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases |
| NL1037643C2 (en) * | 2010-01-22 | 2011-07-25 | Karel Paul Bouter | Nutritional product comprising a biguanide. |
| MA34828B1 (fr) | 2011-01-10 | 2014-01-02 | Zinfandel Pharmaceuticals Inc | Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer |
| US9808434B2 (en) | 2011-01-27 | 2017-11-07 | City Of Hope | Compound for treating cancer and diabetes |
| WO2012103523A2 (en) | 2011-01-27 | 2012-08-02 | Samuel Rahbar | Novel modulators of development of adipocyte and cancer cells |
| US20150038589A1 (en) * | 2011-07-22 | 2015-02-05 | Karel Paul Bouter | Nutritional Product Comprising a Biguanide |
| KR101432246B1 (ko) * | 2011-09-20 | 2014-08-21 | 가톨릭대학교 산학협력단 | 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물 |
| ES2589169B1 (es) * | 2015-05-06 | 2017-08-29 | Instituto De Investigacion Sanitaria - Fundación Jiménez Díaz | Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos |
| WO2019104065A1 (en) * | 2017-11-22 | 2019-05-31 | Turrinii Pharmaceutical, Llc | Anti-aging methods and compositions |
| CN114831930B (zh) * | 2022-03-28 | 2023-09-05 | 厦门大学 | 一种胶原蛋白组装眼药、制备方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5100919A (en) * | 1984-03-19 | 1992-03-31 | The Rockefeller University | Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein |
| JPH062675B2 (ja) * | 1985-04-05 | 1994-01-12 | ヘキストジヤパン株式会社 | 記憶障害治療剤 |
| JPH0798794B2 (ja) * | 1987-04-01 | 1995-10-25 | 大鵬薬品工業株式会社 | タウリン型化合物 |
| US5268500A (en) | 1987-06-15 | 1993-12-07 | Montefiore Medical Center | Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation |
| US4921997A (en) | 1988-06-15 | 1990-05-01 | Montefiore Medical Center | Method of synthesis and novel compounds for pharmaceutical uses |
| US5093367A (en) | 1988-06-15 | 1992-03-03 | Montefiore Medical Center | Method of synthesis and novel compounds for pharmaceutical uses |
| JP3117823B2 (ja) * | 1992-11-17 | 2000-12-18 | 鐘紡株式会社 | コラーゲン代謝賦活剤 |
| JPH0741423A (ja) * | 1993-02-24 | 1995-02-10 | Sankyo Co Ltd | 動脈硬化症治療剤 |
| US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| JPH1029942A (ja) * | 1996-04-02 | 1998-02-03 | Yoichi Ichikawa | 慢性関節リウマチ治療剤 |
| JPH10212247A (ja) * | 1996-05-31 | 1998-08-11 | Sankyo Co Ltd | 自己免疫疾患治療剤 |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6498193B2 (en) * | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
-
2000
- 2000-04-28 CA CA002371391A patent/CA2371391A1/en not_active Abandoned
- 2000-04-28 JP JP2000614987A patent/JP2002543118A/ja active Pending
- 2000-04-28 WO PCT/US2000/011355 patent/WO2000066102A2/en not_active Ceased
- 2000-04-28 AU AU46712/00A patent/AU776162B2/en not_active Ceased
- 2000-04-28 EP EP00928475A patent/EP1210087A2/en not_active Withdrawn
-
2002
- 2002-03-14 US US10/096,580 patent/US20020123501A1/en not_active Abandoned
- 2002-03-14 US US10/096,579 patent/US6693106B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002543118A5 (enExample) | ||
| JP2003530346A5 (enExample) | ||
| CA2274910A1 (en) | Flat medicament preparation for the application and release of buprenorphine or a pharmacologically comparable substance in the buccal cavity, and method of producing the same | |
| DE69110969D1 (de) | Verwendung von Triclosan zur Behandlung von Krankheiten des Gastrointestinaltraktes. | |
| JPH0773480B2 (ja) | アミノ酸をベースとする栄養ペレット | |
| CA2452577A1 (en) | Soft capsules | |
| JP2004506009A5 (enExample) | ||
| ATE289512T1 (de) | Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms | |
| BRPI0513455A (pt) | formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada | |
| CA2439791A1 (en) | Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases | |
| SE8801732D0 (sv) | Ny komposition | |
| RU2003102367A (ru) | Эндопаразитоцидные средства для добровольного орального приема внутрь животными | |
| FR2804603B1 (fr) | Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques | |
| WO2008057300A9 (en) | Trpvi antagonists and uses thereof | |
| JP2000290161A5 (enExample) | ||
| EP1167016A3 (en) | Oxygen absorbable laminate and production method thereof | |
| RU2005117356A (ru) | Способ подавления роста дрожжей | |
| JP2939301B2 (ja) | 経口摂取組成物 | |
| JP5053535B2 (ja) | 寝つきまたは寝起き改善用経口剤 | |
| JP2003522782A5 (enExample) | ||
| JP2007514699A5 (enExample) | ||
| NO20005850L (no) | Fremgangsmåte for konservering av spekeprodukt av marint råstoff | |
| RU2006109556A (ru) | Состав для детского питания | |
| WO2004004705A3 (en) | Pharmaceutical formulations for preparing drink products | |
| Babu et al. | Overview of formulation & evaluation of fast dissolving tablet: A promising tablet dosage form |